{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-005100","form_type":"8-K","ticker":"CNBX","cik":"0001343009","company_name":"CNBX Pharmaceuticals Inc.","filed_at":"2022-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.474179+00:00","generated_at":"2026-06-24T09:05:40.527243+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CNBX appoints Dr. Sanja Goldberg as CTO, replacing Dr. Eyal Ballan","bullets":["Dr. Eyal Ballan resigned as CTO and employment ended effective July 20, 2022.","Dr. Sanja Goldberg appointed as new CTO on July 24, 2022.","Goldberg previously held senior researcher roles at Sheba Medical Center's Cancer Research Lab.","She held executive positions at Compugen and TaGeza Biopharma (VP R&D).","Goldberg earned a Ph.D. in Cell Biology from Erasmus MC, Rotterdam in 2009."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-005100","json":"https://secwatch.observer/filing/0001683168-22-005100.json","markdown":"https://secwatch.observer/filing/0001683168-22-005100.md","text":"https://secwatch.observer/filing/0001683168-22-005100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/cnbx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T09:05:40.527243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2db2a97fbc","claim":"Sanja Goldberg was appointed as Chief Technology Officer at CNBX Pharmaceuticals Inc..","evidence_excerpt":"Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"},{"claim_id":"42dfe70e00","claim":"Eyal Ballan resigned as Chief Technology Officer at CNBX Pharmaceuticals Inc..","evidence_excerpt":"Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}